Analytical Data
-
Gene name
Osteopontin/OPN
-
简介
Osteopontin/OPN is a secretory glycophosphoprotein belonging to the SIBLING family. It contains RGD sequences and phosphorylation sites and can bind to integrins αvβ3, α4β1 and CD44 receptors. Osteopontin/OPN regulates cell adhesion and migration through receptor-mediated regulation, activates MAPK/ERK and PI3K-AKT to promote tumor invasion, and upregulates TIMP-1/2 to inhibit MMPs and protect cartilage. Osteopontin/OPN can be used in the study of osteoarthritis, liver cancer, etc[1][2][3].
- Application
-
Biological Activity
Measured by the ability of the immobilized protein to support the adhesion of HEK293 human embryonic kidney cells. When 1 x 10^5 cells/well are added to Recombinant Human Osteopontin coated plates, cell adhesion is enhanced in a dose dependent manner after 1 hour incubation at 37 °C. The ED50 for this effect is <0.3 μg/mL. Measured by the ability of the immobilized protein to support the adhesion of HEK293 human embryonic kidney cells. When 1 x 105 cells/well are added to Recombinant Human Osteopontin coated plates, cell adhesion is enhanced in a dose dependent manner after 1 hour incubation at 37 °C. The ED50 for this effect is 0.1486 μg/mL, corresponding to a specific activity is 6729.475 units/mg.
-
Alternative Names
Osteopontin; Bone Sialoprotein 1; Nephropontin; Secreted Phosphoprotein 1; SPP-1; Urinary Stone Protein; Uropontin; SPP1; BNSP; OPN
-
Species
Human
-
Source
HEK293
-
Tag
C-6*His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
P10451-1
-
Expression Region
I17-N314
-
AA Sequence
IPVKQADSGSSEEKQLYNKYPDAVATWLNPDPSQKQNLLAPQNAVSSEETNDFKQETLPSKSNESHDHMDDMDDEDDDDHVDSQDSIDSNDSDDVDDTDDSHQSDESHHSDESDELVTDFPTDLPATEVFTPVVPTVDTYDGRGDSVVYGLRSKSKKFRRPDIQYPDATDEDITSHMESEELNGAYKAIPVAQDLNAPSDWDSRGKDSYETSQLDDQSAETHSHKQSRLYKRKANDESNEHSDVIDSQELSKVSREFHSHEFHSHEDMLVVDPKSKEEDKHLKFRISHELDSASSEVN
-
Protein Length
Full Length of Isoform-1 Mature Protein
-
Molecular Weight
50-69 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Osteopontin (OPN) is a glycoprotein that plays a significant role in bone remodeling, immune responses, and various physiological and pathological processes. Its involvement in cellular signaling pathways and its ability to interact with different cell types make it a key player in inflammation, tissue repair, and tumor progression. Research on recombinant OPN protein has gained traction due to its potential applications in biomedical fields, including regenerative medicine and cancer therapy. Recombinant technology facilitates the production of OPN in sufficient quantities for in vitro and in vivo studies, enabling researchers to investigate its functional roles under various conditions. Moreover, the study of OPN is crucial for understanding diseases like osteoporosis, cardiovascular disorders, and certain cancers, where its expression levels often correlate with disease progression and outcomes. By elucidating the molecular mechanisms through which osteopontin operates, scientists aim to develop targeted therapies that can modulate its activity, enhancing therapeutic strategies and improving patient prognosis. The growing body of evidence highlighting OPN's multifaceted roles in both health and disease underscores the importance of further exploring its pathways and therapeutic potential.
